Company / SG&A Expense
ArriVent BioPharma, Inc. SG&A Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$15.3M
FY2024
5-year range
$9.7M / $15.3M
FY2023-FY2024
Trend
+57.7%
vs FY2023
Sector context
#204 of 213
Health Care
What the data says
Among 213 Health Care companies, ArriVent BioPharma, Inc. is in the top 4% for sg&a expense.
Based on SEC 10-K filings.
$15M in FY2024.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $15.3M Sector average $722.3M
▼
-97.9% below sector average
Key checks
Key Insights
- In FY2024, sg&a expense increased 57.7% year-over-year.
- Ranks #204 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.3M | +57.7% |
| FY2023 | $9.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026